SCHEMBL3222842

SCHEMBL3222842

CCOc1ccc2c(c1)C(C)(c1cc(C(=O)N3CCN(C)CC3)ccc1Cl)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 1/20 0.55
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
AVPR1B P47901 6/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
TSHR P16473 1/20 0.36
LRRK2 Q5S007 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235137 0.91 AVPR1A (0.57) AVPR1AALDH1A1SMN1; SMN2LMNATDP1
SCHEMBL3238642 0.90 AVPR1A (0.57) AVPR1AALDH1A1KMT2AAVPR1B
SCHEMBL3239294 0.89 AVPR1A (0.56) AVPR1AALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL3233637 0.89 AVPR1A (0.55) AVPR1ASMN1; SMN2LMNAMEN1KMT2A
SCHEMBL3223097 0.89 AVPR1A (0.54) AVPR1AALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL3234052 0.89 AVPR1A (0.55) AVPR1ASMN1; SMN2LMNAMAPK1MEN1
SCHEMBL3233606 0.89 AVPR1A (0.55) AVPR1ASMN1; SMN2LMNATDP1L3MBTL1
SCHEMBL3227252 0.87 AVPR1A (0.57) AVPR1AALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL3230051 0.87 AVPR1A (0.55) AVPR1ASMN1; SMN2LMNAMEN1KMT2A
SCHEMBL3237260 0.86 AVPR1A (0.56) AVPR1ASMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097374-B1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI AVENTIS (FR) 2010-06-09 EP disclosed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US disclosed
EP-2097374-A2 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS Sanofi-Aventis (FR) 2009-09-09 EP disclosed
WO-2008087278-A2 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI-AVENTIS (FR) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AVPR2, AVPR1A, AVPR1B AVPR1A 2/4885ALDH1A1 3212/4885SMN1; SMN2 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.